Carcinoembryonic Antigen (CEA) Market By Application - Global Industry Analysis and Forecast to 2027
Published On : October 2017 Pages : 93 Category: Biotechnology Report Code : HC10279
Industry Outlook and Trend Analysis
The Carcinoembryonic Antigen (CEA) Market was worth USD 1.36 billion in the year of 2017 and is expected to reach approximately USD 2.51 billion by 2022, while registering itself at a compound annual growth rate (CAGR) of 5.64% during the forecast period. The Global carcinoembryonic antigen market is anticipated to encounter significant development over the estimate time on account of factors like increasing predominance of cancer and the advancement of novel biomarkers. Evaluations distributed by the World Health Organization, recommend that in 2017, the overall cancer occurrences were almost 14.1 Million, which included 7.4 million male and 6.7 million female patients. The world Age-Standardized (AS) rate reflects that there are about 205 new cases of cancer for each 100,000 men globally, and 165 for each 100,000 women. Moreover, the existence of ideal government activities relating to the awareness of cancer and control by associations, for example, the National Cancer Institute, and the Cancer Prevention and Control Research Network (CPCRN) is relied upon to emphatically fortify market development. Advancement of novel biomarkers which can be utilized as a part of mix with different biomarkers is probably going to play a significant part in driving business sector development over the gauge time frame. Quickly expanding aged populace base inclined to endless therapeutic conditions including cancer is probably going to extend the purchaser base. Technological enhancements in proteomics including mass spectrometry, protein bioinformatics, imaging, array based methodologies, and labeling of protein have enabled scientists to quickly find more biomarkers and to better comprehend their parts. Furthermore, presentation and steady advancement of novel immunological procedures, for example, the radioimmunoassay is anticipated to elevate the requirement for carcinoembryonic antigen tests over the figure time frame.
Application Outlook and Trend Analysis
Major applications sections of the carcinoembryonic antigen market comprise thyroid cancer, pancreatic cancer, breast cancer, colorectal cancer and ovarian cancer among others. In 2017, the market was dominated by carcinoembryonic antigen for colorectal cancer on the basis of revenue. Major factors that contribute to its vast share are growing demand for minimally obtrusive diagnostic methods, increasing aged population, rising predominance of unhealthy ways of life like irregular eating patterns. Moreover, the consumption of alcohol and inactive lifestyle may be the reason behind the growth of colorectal cancer in the upcoming years. Breast cancer is anticipated to be the rapidly developing segment and is foreseen to encounter substantial growth in the following years.
Regional Outlook and Trend Analysis
Leading regional segments in of carcinoembryonic antigen market are Latin America, Europe, MEA, Asia Pacific and North America. The global market was dominated by North America on the basis of revenue in 2017 with a share of 46.3 percent due to high occurrence rates of cancer, existence of advanced healthcare framework and increasing awareness in patients. The existence of undiscovered opportunities, continuously enhancing healthcare framework, monetary improvement, and growing awareness in patients are a few elements representing this fast development. Moreover, yearly rates of colorectal cancer all around are more than 1 million and this rate is additionally anticipated to increase. The death rate recorded was around 490,000 of every 1990 and 715,000 out of 2017. Asia Pacific holds the most elevated rate of mortality, joined by North America. As indicated by the information distributed by the American Cancer Society in 2017, it has been assessed that the death rate of all types of cancers has kept on declining which began in mid-1990s. Asia Pacific has had a major influence on the market on the basis of cancer occurrence rates that affect a vast population at a rate that is changeable in 2017.
Competitive Insights
Major players in the market are Abbott Diagnostics, Quest Diagnostics and Roche Holding AG. Industry competition levels for this market are relied upon to stay at a respectably high level amid the estimate time frame. The market is united in nature and is therefore, set apart by a broad existence of acquisitions and mergers. These efforts are relied upon to raise the level of competition among key players. Makers confront thorough cost based rivalry and are likewise under steady pressure to present new and technologically propelled items.
The global Carcinoembryonic Antigen market is segmented as follows-
By Application
- CEA Based Pancreatic Cancer
- CEA Based Ovarian Cancer
- CEA Based Thyroid Cancer
- CEA Based Colorectal Cancer
- CEA Based Breast Cancer
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2022?
- What will be the industry market growth from 2017 to 2022?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
- Carcinoembryonic Antigen (CEA) Market, By Application, Estimates and Forecast, 2012-2022 ($Million)
- CEA Based Pancreatic Cancer
- CEA Based Ovarian Cancer
- CEA Based Thyroid Cancer
- CEA Based Colorectal Cancer
- CEA Based Breast Cancer
- Other Applications
- Carcinoembryonic Antigen (CEA) Market, By Region, Estimates and Forecast, 2012-2022 ($Million)
- North America
- North America Carcinoembryonic Antigen (CEA) Market, By Country
- North America Carcinoembryonic Antigen (CEA) Market, By Application
- U.S. Carcinoembryonic Antigen (CEA) Market, By Application
- Canada Carcinoembryonic Antigen (CEA) Market, By Application
- Mexico Carcinoembryonic Antigen (CEA) Market, By Application
-
- Europe
- Europe Carcinoembryonic Antigen (CEA) Market, By Country
- Europe Carcinoembryonic Antigen (CEA) Market, By Application
- Germany Carcinoembryonic Antigen (CEA) Market, By Application
- France Carcinoembryonic Antigen (CEA) Market, By Application
- UK Carcinoembryonic Antigen (CEA) Market, By Application
- Italy Carcinoembryonic Antigen (CEA) Market, By Application
- Spain Carcinoembryonic Antigen (CEA) Market, By Application
- Rest of Europe Carcinoembryonic Antigen (CEA) Market, By Application
-
- Asia-Pacific
- Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Country
- Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Application
- Japan Carcinoembryonic Antigen (CEA) Market, By Application
- Australia Carcinoembryonic Antigen (CEA) Market, By Application
- India Carcinoembryonic Antigen (CEA) Market, By Application
- South Korea Carcinoembryonic Antigen (CEA) Market, By Application
- Rest of Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Application
- Asia-Pacific
-
- Rest of the World
- Rest of the World Carcinoembryonic Antigen (CEA) Market, By Country
- Rest of the World Carcinoembryonic Antigen (CEA) Market, By Application
- Brazil Carcinoembryonic Antigen (CEA) Market, By Application
- South Africa Carcinoembryonic Antigen (CEA) Market, By Application
- Saudi Arabia Carcinoembryonic Antigen (CEA) Market, By Application
- Turkey Carcinoembryonic Antigen (CEA) Market, By Application
- United Arab Emirates Carcinoembryonic Antigen (CEA) Market, By Application
- Others Carcinoembryonic Antigen (CEA) Market, By Application
- Rest of the World
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Increasing Geriatric Population
3.2.1.2. Rising Incidence Of Cancer
3.2.1.3. Increasing Demand for Minimally Invasive
3.2.2. Restraints
3.2.2.1. Stringent Regulations
3.2.2.2. Inefficiency in Detecting Cancer at Early Stages
3.2.3. Opportunities
3.2.3.1. Emerging Countries to Offer Lucrative Growth Opportunities
4. Carcinoembryonic Antigen (CEA) Market, By Application
4.1. Introduction
4.2. Carcinoembryonic Antigen (CEA) Market Assessment and Forecast, By Application, 2012-2022
4.3. CEA Based Pancreatic Cancer
4.3.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.4. CEA Based Ovarian Cancer
4.4.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.5. CEA Based Thyroid Cancer
4.5.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.6. CEA Based Colorectal Cancer
4.6.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.7. CEA Based Breast Cancer
4.7.1. Market Assessment and Forecast, By Region, 2012-2022 ($Million)
4.8. Other Application
4.8.1. Market Assessment and Forecast, By Type, 2012-2022 ($Million)
5. Carcinoembryonic Antigen (CEA) Market, By Region
5.1. Introduction
5.2. Carcinoembryonic Antigen (CEA) Market Assessment and Forecast, By Region, 2012-2022 ($Million)
5.3. North America
5.3.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.3.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.3.3. U.S.
5.3.3.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.3.4. Canada
5.3.4.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.3.5. Mexico
5.3.5.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4. Europe
5.4.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.4.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.3. Germany
5.4.3.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.4. France
5.4.4.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.5. UK
5.4.5.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.6. Italy
5.4.6.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.7. Spain
5.4.7.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.4.8. Rest of Europe
5.4.8.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5. Asia-Pacific
5.5.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.5.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.3. Japan
5.5.3.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.4. China
5.5.4.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.5. Australia
5.5.5.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.6. India
5.5.6.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.7. South Korea
5.5.7.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.5.8. Rest of Asia-Pacific
5.5.8.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6. Rest of the World
5.6.1. Market Assessment and Forecast, By Country, 2012-2022 ($Million)
5.6.2. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.3. Brazil
5.6.3.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.4. Turkey
5.6.4.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.5. Saudi Arabia
5.6.5.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.6. South Africa
5.6.6.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.7. United Arab Emirates
5.6.7.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
5.6.8. Others
5.6.8.1. Market Assessment and Forecast, By Application, 2012-2022 ($Million)
6. Company Profiles
6.1. Quest Diagnostics
6.1.1. Business Overview
6.1.2. Product Portfolio
6.1.3. Key Financials
6.1.4. Strategic Developments
6.2. Roche Diagnostics
6.2.1. Business Overview
6.2.2. Product Portfolio
6.2.3. Key Financials
6.2.4. Strategic Developments
6.3. Abbott Diagnostics
6.3.1. Business Overview
6.3.2. Product Portfolio
6.3.3. Key Financials
6.3.4. Strategic Developments
6.4. GenWay Biotech Inc.
6.4.1. Business Overview
6.4.2. Product Portfolio
6.4.3. Strategic Developments
6.5. Correlogic Systems, Inc.
6.5.1. Business Overview
6.5.2. Product Portfolio
6.5.3. Strategic Developments
List of Tables
Table 1.Carcinoembryonic Antigen (CEA) Market, By Application ($Million), 2012-2022
Table 2.CEA Based Pancreatic Cancer Market, By Region ($Million), 2012-2022
Table 3.CEA Based Ovarian Cancer Market, By Type ($Million), 2012-2022
Table 4.CEA Based Thyroid Cancer Market, By Region ($Million), 2012-2022
Table 5.CEA Based Colorectal Cancer Market, By Region ($Million), 2012-2022
Table 6.CEA Based Breast Cancer Market, By Region ($Million), 2012-2022
Table 7.Other Application Market, By Region ($Million), 2012-2022
Table 8.North America Carcinoembryonic Antigen (CEA) Market, By Country, 2012-2022 ($Million)
Table 9.North America Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 10.U.S.Carcinoembryonic Antigen (CEA) Market, by Application, 2012-2022 ($Million)
Table 11.Canada Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 12.Mexico Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 13.Europe Carcinoembryonic Antigen (CEA) Market, By Country, 2012-2022 ($Million)
Table 14.Europe Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 15.Germany Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 16.France Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 17.UK Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 18.Italy Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 19.Spain Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 20.Rest of Europe Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 21.Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Country, 2012-2022 ($Million)
Table 22.Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 23.Japan Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 24.China Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 25.Australia Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 26.India Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 27.South Korea Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 28.Rest of Asia-Pacific Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 29.Rest of the World Carcinoembryonic Antigen (CEA) Market, By Country, 2012-2022 ($Million)
Table 30.Rest of the World Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 31.Brazil Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 32.Turkey Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 33.Saudi Arabia Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 34.South Africa Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 35.United Arab Emirates Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 36.Others Carcinoembryonic Antigen (CEA) Market, By Application, 2012-2022 ($Million)
Table 37.Quest Diagnostics: Key Strategic Developments, 2017-2017
Table 38.Roche Diagnostics: Key Strategic Developments, 2017-2017
Table 39.Abbott Diagnostics: Key Strategic Developments, 2017-2017
Table 40.GenWay Biotech Inc.: Key Strategic Developments, 2017-2017
Table 41.Correlogic Systems, Inc.: Key Strategic Developments, 2017-2017
List of Figures
Figure 1.Carcinoembryonic Antigen (CEA) Market Share, By Application, 2017 & 2025
Figure 2.Carcinoembryonic Antigen (CEA) Market, By Region, 2017, ($Million)
Figure 3.Quest Diagnostics: Net Revenues, 2017-2017 ($Million)
Figure 4.Quest Diagnostics: Net Revenue Share, By Segment, 2017
Figure 5.Quest Diagnostics: Net Revenue Share, By Geography, 2017
Figure 6.Quest Diagnostics: Net Revenues, 2017-2017 ($Million)
Figure7.Roche Diagnostics: Net Revenue Share, By Segment, 2017
Figure8.Roche Diagnostics: Net Revenue Share, By Geography, 2017
Figure9.Roche Diagnostics: Net Revenues, 2017-2017 ($Million)
Figure 6.Abbott Diagnostics: Net Revenues, 2017-2017 ($Million)
Figure10.Abbott Diagnostics: Net Revenue Share, By Segment, 2017
Figure 11.Abbott Diagnostics: Net Revenue Share, By Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|